Provided by Tiger Trade Technology Pte. Ltd.

Context Therapeutics Inc.

0.5001
-0.0196-3.77%
Post-market: 0.5000-0.0001-0.02%19:31 EDT
Volume:1.75M
Turnover:903.56K
Market Cap:45.95M
PE:-1.04
High:0.5469
Open:0.5269
Low:0.5000
Close:0.5197
52wk High:3.62
52wk Low:0.4320
Shares:91.88M
Float Shares:63.73M
Volume Ratio:0.75
T/O Rate:2.74%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.4828
EPS(LYR):-0.3800
ROE:-76.14%
ROA:-45.70%
PB:1.20
PE(LYR):-1.32

Loading ...

Context Therapeutics (CNTX) Gets a Buy from Guggenheim

TIPRANKS
·
May 07

Analysts Are Bullish on These Healthcare Stocks: Mineralys Therapeutics, Inc. (MLYS), Context Therapeutics (CNTX)

TIPRANKS
·
May 07

Context Therapeutics Q1 net loss widens 90% to $8.68 million

Reuters
·
May 07

Context Therapeutics Q1 net loss widens on higher R&D costs

Reuters
·
May 07

Context Therapeutics - Cash and Cash Equivalents of $54.5 Mln as of March 31, 2026 Expected to Fund Operations Into Mid-2027

THOMSON REUTERS
·
May 07

Context Therapeutics Inc. Q1 Basic EPS USD -0.09

THOMSON REUTERS
·
May 07

Context Therapeutics settles governance lawsuit with mootness fee

TIPRANKS
·
May 02

Context Therapeutics litigation ends with $850,000 mootness fee paid by provider

Reuters
·
May 02

Context Therapeutics Inc expected to post a loss of 12 cents a share - Earnings Preview

Reuters
·
Apr 30

Context Therapeutics announces annual shareholder meeting

Reuters
·
Apr 18

Neogen names Jennifer Evans Stacey chief legal, compliance officer, board secretary

Reuters
·
Apr 08

JonesTrading Remains a Buy on Context Therapeutics (CNTX)

TIPRANKS
·
Apr 07

Analysts Are Bullish on These Healthcare Stocks: Femasys (FEMY), Context Therapeutics (CNTX)

TIPRANKS
·
Apr 02

Context Therapeutics Gains FDA Fast Track for CTIM-76

TIPRANKS
·
Apr 02

Context Therapeutics granted Fast Track Designation to CTIM-76 by FDA

TIPRANKS
·
Apr 02

Context Therapeutics’ CTIM-76 wins FDA fast-track status for platinum-resistant ovarian cancer

Reuters
·
Apr 02

Context Therapeutics - Ctim-76 Phase 1a Trial Ongoing, Interim Data Expected June 2026

THOMSON REUTERS
·
Apr 02

Context Therapeutics Announces Ctim-76 Receives FDA Fast Track Designation for the Treatment of Platinum-Resistant Ovarian Cancer

THOMSON REUTERS
·
Apr 02

Calendar of U.S. Earnings Expected in the Week Ahead

Dow Jones
·
Mar 25

Guggenheim Reaffirms Their Buy Rating on Context Therapeutics (CNTX)

TIPRANKS
·
Mar 24